Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …

Objectives Current evidence indicates that the pharmacokinetic profile of rivaroxaban is not
significantly impacted by body weight. However, real-world data are needed to better assess …

Background Considering that the current fixed dose of direct oral anticoagulants (DOACs)
might have insufficient anticoagulation effect for overweight patients, the aim of this study …

Background: Although rivaroxaban has demonstrated consistent drug levels in normal
weight and obese patients, sufficient confirmation of equal clinical effectiveness and safety is …

Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

Background Current evidence suggests that rivaroxaban may be well tolerated and effective
in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited …

Background: The International Society of Thrombosis and Haemostasis recommends
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …

Background Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …

Background: Direct oral anticoagulants (DOACs) have been increasingly preferred over
warfarin; however, The International Society of Thrombosis and Hemostasis recommended …

Introduction Current evidence indicates that rivaroxaban may be a safe and effective
alternative to warfarin among patients with nonvalvular atrial fibrillation (NVAF) and obesity …